Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
Pharma companies add new members to executive ranks and boards of directors.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations Act in May 2019 has been sentenced.
The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.
The biosimilar candidate, IBI305, completed a Phase III study in China and was granted Priority Review by that country’s National Medical Products Administration.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
In a filing this week, the government said that tens of thousands of patients received “unreliable blood tests,” which deprived them of money and placed their health at risk.
The company’s chief executive officer, Ludwig Hantson, admits it’s a longshot.